For over 25 years, Gary Winer has been proving his leadership abilities in the medical device, laboratory diagnostics and pharmaceutical industries on an international platform that includes such notable markets as the United States, Latin America, Asia, and Japan.
Over the years, Gary made significant leadership impact and increased revenues for such Fortune 500 Companies as AbbVie, Abbott, Pharmacia, Searle and Baxter, helping launch and promote such notable brands as Humira and Celebrex. Most recently, he served as Vice President, Commercial Strategic Projects for AbbVie, and immediately prior to that assignment was President and CEO of AbbVie and Abbott’s $1B Japanese operations. He brings extensive general management experience, with broad knowledge in commercial, product development, regulatory and organizational effectiveness aspects of healthcare business operations.
Today, Gary offers his leadership abilities to other life science companies that want to achieve aggressive, sustainable growth while creating a positive corporate culture. With his extensive experience in international markets, he understands the key performance indicators, regulatory requirements and cultural sensitivity necessary to make gains in the global marketplace.
Gary holds an undergraduate degree in Finance from California State University, Northridge and an MBA from Northwestern’s Kellogg Graduate School of Management.
Michael S. Rosen
Michael is Managing Director of Rosen Biosciences Strategies, a life science economic development consultancy focusing on enabling international life science companies to enter the U.S. market and assist U.S. companies globalize, and the development of science parks and clusters. Prior to this, for approximately 9 years, he was Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises, a U.S. real estate development company which develops and builds science parks across the U.S. Mr. Rosen worked with key research universities affiliated with Forest City parks, such as Johns Hopkins (Baltimore), MIT (Boston), and Northwestern University (Chicago), and successfully brought numerous life science companies from Germany, Japan and New Zealand into these parks.
During his many years in the life sciences industry, he has spent 20 years in senior management positions with Pfizer, Bristol-Myers Squibb and Searle/Monsanto, and lived in Latin America, Japan, and Europe, and worked extensively in Canada, and Asia. Mr. Rosen spent 12 years as President/CEO of European and U.S. biotech and medical device companies in the areas of cancer, cardiology, neuroscience, woundcare and kidney disease.
Mr. Rosen is a founder, former Vice-Chairman and board member of the Illinois Biotechnology Industry Organization, and a member of the board and Sr. Vice-President of the America-Israel Chamber of Commerce – Chicago. He is a former member of the Industry Advisory Board for Northwestern University’s Masters of Biotechnology Program, and is currently an adjunct professor of biotechnology at Northwestern, and former professor of international management and marketing at Lake Forest Graduate School of Management; where he led their annual program in Brazil for the 8y ears to the Business School of Sao Paulo (BSP). He has organized and participated in multiple Illinois & Maryland Trade Missions to Canada, Ireland, Israel, Germany, India, Japan, China, Taiwan and Brazil. He is currently a Partner Consultant of Aagami, an Indian-U.S. life science business development consultancy.
He received his B.A. in Sociology and International Relations from Beloit College and an M.B.A. in International Business from the University of Miami. He has post-graduate studies at Northwestern University, Sophia University (Tokyo, Japan) and Universidad Tecnica Federico Santa Maria (Santiago, Chile)
Jim is the co-founder and Managing Partner of Symons Markwith LLP’s Seattle and Washington, DC offices. The firm’s clients range from startups to the largest electronic commerce and cloud computing company in the world, and represent a range of industries and offerings, including computer software, Healthcare IT, data analytics, standards development organizations (SDOs), open source software developers, and other emerging technologies and services.
Jim is an Adjunct Professor at the Santa Clara University School of Law, where he teaches and mentors for the Entrepreneurs’ Law Clinic. Jim also serves as General Counsel to the CommonWell Health Alliance, a non-profit industry alliance promoting a national electronic healthcare record infrastructure in the U.S.
Prior to private practice, Jim served as Senior Vice President and Chief IP Counsel for Allscripts Healthcare, and held senior in-house legal positions with Microsoft, GE Healthcare IT and Adobe Systems. Jim received his Juris Doctor degree from the Santa Clara University School of Law, and is a Member of the California, Washington, DC, and Washington state Bars.
Emily Miao, Ph.D.
Dr. Miao is a partner with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Miao has over 20 years of experience in all aspects of intellectual property practice, including patent, trademark and copyright procurement and portfolio management; client counseling on validity, infringement, freedom-to-operate (FTO), due diligence reviews, and patent strategy matters; and licensing/secrecy agreements. She represents many companies, both large and small, and Universities and is particularly experienced in representing start-up companies in prosecution, counseling, and licensing. Her recent cases have involved biotechnology, pharmaceuticals, biologicals, diagnostic systems, molecular biology, drug delivery systems, medical devices, nanotechnology, and chemical and food processes.
Dr. Miao serves as speaker, moderator, or panelist at industry events relating to Intellectual property matters. Dr. Miao also serves as a judge at the Northwestern University's Venture Challenge and Entrepreneur Idol events. She is a member of Chicago Innovation Mentors (CIM), a division of the MATTER Chicago organization which promotes entrepreneurship, innovation and commercialization to improve healthcare. As a CIM mentor, she frequently works with start-ups and small companies on intellectual property matters including patent licensing, research agreements, patent protection, and trade secret protection. She is also actively involved Women in Bio (WIB), a national organization committed to promoting careers, leadership and entrepreneurship for women in the life sciences, and serves on the WIB Chicago Chapter Board of Directors.
Cate Brady, Entrepreneur
Cate Brady has over 20 years’ experience working in start-up companies that bring
disruptive technologies to the market. She consults to limited number of clients in new
technology and digital health sectors. Most recently she has worked with health care
companies either in product planning or product and company launch. Her first digital
health company was as an advisor to a 2001 company providing decision support for
customers of medical insurance companies such as UniCare, Wellpoint, and the Blue
Cross companies. Subimo was purchased by WebMD in 2007.
She started her entrepreneurial career as the co-founder of a software technology
company that was one of the first to combine voice and data over computer networks.
This company, Apropos Technology, went public in 2000 and was sold in 2004.
As an angel investor she is involved with digital health companies, financial and
transaction technology platforms, and an international social network company. Cate is
also the co-founder and board member of Bulk Ag Innovations, a Midwestern
manufacturing company creating proprietary products for materials handling industries
Cate was named one of the Top 25 Chicago Women in Technology in 2001. She has
certificate from the Kellogg School of Management, Women Director Program, an MS in
Finance, a BS in Economics and studied Interior Architecture at the School of the Art
Institute of Chicago in 2007 and 2008.
Hiroshi Uchida, Ph.D.
Dr. Hiroshi Uchida has more than 25 years’ of experience leading change and transformation in the global medical technology, in-vitro diagnostics (IVD), and other industries by way of management consulting .Dr. Uchida has been creating foundations for sustainable financial performance by solving complex business issues, driving strategic redirections and building new partnerships.
With expertise in business development, alliance building, organizational restructuring and advanced technology, Hiroshi consistently drives lasting improvements for his clients. Dr. Uchida started his career by turning around consulting company offices; and later, critically led in the restructuring of Dade Behring out of Chapter 11, a transformation that yielded over 600% stock increase.
With Immucor, a global in vitro diagnostics company specializing in the areas of transfusion and transplant diagnostics; Hiroshi’s latest accomplishment focuses on integrating and transforming the transplant diagnostics business, by reprioritizing the existing R&D portfolio, and through acquiring innovation and cutting technology such bio-markers or next generation sequencing for breakthrough growth. He also built a scientific expert team with an innovation focus to continue new product launches and commercialization for growth.
While President and Chief Executive Officer of a small/ mid-sized clinical-diagnostics company, Magellan Biosciences, he strengthened operations and spearheaded the strategic sale of the company’s microbiology business to Thermo Fisher Scientific. Prior to Magellan, Hiroshi held various senior positions, the last position being the Chief Technology Officer, for Fenwal, a medical company in the transfusion collection equipment business. Before Fenwal, Hiroshi held various executive leadership positions in commercial and operation & supply chain at Dade Behring.
Presently, in addition to Immucor, Hiroshi holds a Senior Advisor role and Board member at both, VMock, and Roosery, and an advisor and member of CEO council at Driehaus Privare Equity as well as scientific advisor at Miacom Diagnostics where he is supporting to develop growth strategy road maps for driving business to the next level as well as operational consulting.
Dr. Uchida holds both a Ph.D. in Business Studies and Sociology, and a Master’s Degree in Sociology from Harvard University.
Kapila Viges, Director EnterpriseWorks Chicago
As an engineer, entrepreneur and economic developer, Kapila Viges has over 15 years of experience in starting and growing early stage technology companies, organizational strategy, and innovation based economic development policy. Kapila has directly funded, raised funds for, and managed early stage startups, incubators, accelerators, research parks and entrepreneurial support organizations. With experience from early stage companies Kapila brings an industry perspective to her program and policy work.
In her current role as Director of EnterpriseWorks Chicago at the University of Illinois, Kapila has launched a new model for technology and startup incubation operations to support the commercialization of complex research and high-tech innovation. Serving both the University and surrounding region, EnterpriseWorks Chicago is working to create a pipeline supporting viable high-tech startups from the lab to the marketplace. Kapila is working to accelerate the social and economic impact of cutting edge research on the community while also serving as Director of the Proof of Concept Fund for IllinoisVENTURES.
Kapila received her degree in Materials Science and Engineering at The Johns Hopkins University in Baltimore and is an Executive Scholar from the Northwestern Kellogg School of Management.
William Kohlbrenner, PhD
Dr. Kohlbrenner is currently CSO of Life Science Nation (LSN), a Boston-based company that provides a uniquely differentiated suite of services for emerging life science companies. His role at LSN involves technical vetting of potential clients and working with established clients to best position their early-stage companies for successful transactions with investors or large technology/pharma companies. Bill is also an LSN Advisory Board member and Consulting Scientist for Boston Innovation Capital, a broker/dealer that was spun out of LSN in 2014 to address an unmet need among early stage scientist-entrepreneurs for hands-on assistance in executing fundraising campaigns in the biotech and medtech arenas.
Prior to joining LSN in 2014, Dr. Kohlbrenner was a director at AbbVie (Abbott pharma) where he was involved in identifying and pursuing external research opportunities and early-stage assets around the globe. This work included leading a global scouting team and conducting strategic assessments of early- and late-stage pipeline opportunities in multiple therapeutic areas. Earlier in his career, Bill led drug discovery research programs in several areas, including oncology, antivirals and antibacterials. As a director in the Cancer Research area, he was involved in the identification of novel cancer targets and the exploration of nanotechnology-based anti-cancer therapies. Bill was extensively involved in setting up and managing external collaborations with universities, research institutes and biotechs world-wide to support the projects he was leading.
Dr. Kohlbrenner has co-authored numerous research articles examining the fundamental aspects of various drug targets and the molecular basis of drug action. In 2014 he was an invited member of a working group assembled by the President’s Council of Advisors on Science and Technology (PCAST) to conduct the fifth legislatively mandated strategic assessment of the National Nanotechnology Initiative. He received his Ph.D. from the State University of New York (SUNY) and completed postdoctoral training at the Molecular Biology Institute at UCLA.
Mr. Luminiello is a healthcare executive with nearly 30 years of experience in biopharma, medical devices, nutritional supplements, mRNA diagnostics and medical predictive algorithms. Mr. Luminiello has served in key strategic leadership positions in all facets of commercialization, life cycle management, and foreign affiliate start-up. Mr. Luminiello is currently CEO of Third Coast Therapeutics, a start-up company with technology licensed from Northwestern University. Third Coast discovers and develops small molecules designed to prevent the motility of cancer cells.